Business
Establishment Labs Provides Preliminary First Quarter Results and Announces an Investor Day on June 12
NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and
About this update from Establishment Labs Holdings Inc.
[{"type":"text","content":" NEW YORK--(BUSINESS WIRE)--\nEstablishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, provided preliminary first quarter 2025 sales results and announced that it will host an analyst and investor event in New York City on June 12, 2025.\n\nEstablishment Labs’ preliminary unaudited revenue for the first quarter of 2025 is expected to be approximately $41.4 million, including approximately $6.2 million from Motiva sales in the United States.\n\nOn June 12, Establishment Labs’ leadership team and invited plastic surgeons will present an update on the recent launch of Motiva in the United States, the company’s innovation roadmap, and the financial outlook. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the \"Investors\" section of the Establishment Labs website at www.establishmentlabs.com. In-person attendance at the event is limited and requires advanced registration. Please email: [email protected] for further information.\n\n“The second quarter appears strong, and the United States launch continues to accelerate,” said Peter Caldini, Establishment Labs’ Interim CEO. “Average orders in March surpassed 100 per day, and we expect this growth to continue, making our launch one of the fastest in aesthetic history. We have not seen any disruption to our business from recent events and affirm our previous commentary and guidance on revenue of $205 to $210 million for 2025. As currently contemplated, tariffs would represent less than a 50-basis point gross margin impact and do not change our trajectory of turning EBITDA positive in 2025 and cash flow positive in 2026. At our investor day, we look forward to providing an update on our United States launch as well as detailing our pipeline, timeline, and launch strategy for the additional products coming to market in the United States.”\n\nAbout Establishment Labs\n\nEstablishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countr...